PURPOSE: Advancements in orthoplastic reconstructive surgery have enabled surgeons to perform limb salvage surgery successfully after long bone tumor extirpation of upper extremities. A variety of reconstructive options (allograft, prosthetics, allograft-prosthetic combination, non-vascularized autografts) exist for surgical rehabilitation of such cases. Even though reconstruction by prosthesis is most commonly used in this setting, the associated risks of mechanical failure, aseptic loosening, and infection, can potentially lead to failure and amputation. Furthermore, revision procedures of the primary surgery after implant failure are complicated by unfavorable local tissue properties like massive bone loss, unreliable local tissue, and osteopenic process of the host bone. Therefore, prosthetic reconstruction is usually undesirable; whereas vascularized bone flaps have proven to be an excellent alternative to restore the biomechanical framework of the limb. Herein, we present the free fibula flap (FFF) used to reconstruct oncological humeral defects previously treated with prosthetic based reconstruction which failed. METHOD: We conducted a retrospective review of patients who underwent salvage of the humeral reconstructions in which the prosthesis failed, during 2009 and 2019. We included patients with previous reconstruction of humeral defects only with prosthetic material and no tissue transfer. All cases were reconstructed with the FFF. The Musculoskeletal Tumor Society (MSTS) scoring system was used to evaluate functional outcomes. RESULTS: The mean age was 24 ± 5.54 years. Six male patients (85.7%) and one female were included (14.3%). None of the patients had comorbidities. Four patients had primitive neuro-ectodermal tumors (57.1%) while three had osteogenic sarcomas (42.9%). All patients had the radial nerve preserved during onco-resection. The average gap between implant surgery and salvage with FFFs was 77.5 ± 49.024 months. The indications for salvage with the FFF were infection of implants (42.9%) and aseptic loosening (57.1%). The defects were located proximally in seven patients (85.7%) and mid-shaft in one patient (14.3%). Seven patients had adjuvant chemotherapy (85.7%), while two had neoadjuvant radiotherapy (28.6%). The defect length after debridement and implant removal was 13 ± 5.62 cm. The fibula head was incorporated in 57.1% of the flaps (n=4). For flap fixation dynamic compression plates was used in one patient (14.3%); number 20 cerclage wiring, prolene mesh, and ethibond was used in another patient (14.3%); K wires were used in four patients (57.1%); and ethibond in 1 patient (14.3%). Only one flap had a double venous anastomosis. Two patients underwent re-exploration of the anastomosis (57.1%), the only flap harvested with a skin paddle required debridement of the cutaneous component (14.3%), and one patient had wound dehiscence (14.3%). Six flaps survived (85.7%). Bone union was achieved at 17 ± 1.25 weeks on average. The average MSTS score was 74.9%. The average follow up was 59.57 ± 43.48 months. CONCLUSION: The FFF is a resourceful alternative for the management of a failed prosthesis after oncologic resection of the proximal and mid-humerus, especially with previously infected prosthetic material. Due to its anatomical shape and the vascularized nature of tissue, the FFF provides a long bone segment for humeral reconstruction.
Read full abstract